May 10, 2024 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is highlighting a study published in Neuroradiology that validates the benefit of IB Rad Tech for distinguishing treatment effect from tumor progression in post-treatment glioma patients. The lead author, Siem Herings, is a lab member of Dr. Dylan Henssen, MD PhD, at the Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
The research, involving 50 glioma patients, demonstrates that the approach effectively differentiates between treatment-related abnormalities (TRA) and tumor progression (TP). This distinction is critical for determining the appropriate treatment course for patients following surgery and chemoradiotherapy.
Historically, methodssuch asthe ‘hotspot’ or visual approach have been subject to oversimplification and subjectivity. The study’s findings suggest that analyzing the perfusion of the complete lesion with Volume of Interest (VOI), which is made easy with IB Rad Tech, offers a more objective and accurate alternative.
The study team used the recommended consensus protocol, published in 2020, for acquiring DSC data. For post-processing the data, a streamlined IB Rad Tech workflow was used that included IB Delta T1 maps and IB Neuro’s quantitative MR perfusion technology. The authors of the study leveraged IB Rad Tech to provide a repeatable and efficient post-processing approach. Specifically, the workflow included IB Delta T1 maps, which left little room for inter-operator variability when defining enhancing regions, and IB Neuro which is known to produce highly reproducible and quantitative relative cerebral blood volume (rCBV) values that do not rely on the manual placement of a reference region of interest (ROI) to normalize the data.
“This is an excellent study that clearly shows the clinical benefit of standardizing on a common DSC acquisition and post-processing approach using IB Rad Tech to help make critical treatment decisions,” said Michael Schmainda, CEO of IB.
–END–
About Imaging Biometrics® LLC:
IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.